N
Naseem J. Zojwalla
Researcher at Merck & Co.
Publications - 16
Citations - 1098
Naseem J. Zojwalla is an academic researcher from Merck & Co.. The author has contributed to research in topics: Clear cell renal cell carcinoma & Renal cell carcinoma. The author has an hindex of 9, co-authored 16 publications receiving 745 citations. Previous affiliations of Naseem J. Zojwalla include Onyx Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Targeting renal cell carcinoma with a HIF-2 antagonist
Wenfang Chen,Haley Hill,Alana Christie,Min Kim,Eboni Holloman,Andrea Pavia-Jimenez,Farrah Homayoun,Yuanqing Ma,Nirav V. Patel,Paul Yell,Guiyang Hao,Qurratulain Yousuf,Allison Joyce,Ivan Pedrosa,Heather Geiger,He Zhang,Jenny Chang,Kevin H. Gardner,Richard K. Bruick,Catherine Reeves,Tae Hyun Hwang,Kevin D. Courtney,Eugene P. Frenkel,Xiankai Sun,Naseem J. Zojwalla,Tai Wong,James P. Rizzi,Wallace Eli M,John A. Josey,Yang Xie,Xian Jin Xie,Payal Kapur,Renée M. McKay,James Brugarolas +33 more
TL;DR: It is shown that some ccRCCs are HIF-2 independent, and set the stage for biomarker-driven clinical trials, using a tumourgraft/patient-derived xenograft platform to evaluate PT2399, a selective Hif-2 antagonist that was identified using a structure-based design approach.
Journal ArticleDOI
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Kevin D. Courtney,Jeffrey R. Infante,Elaine T. Lam,Robert A. Figlin,Brian I. Rini,James Brugarolas,Naseem J. Zojwalla,Ann M. Lowe,Keshi Wang,Wallace Eli M,John A. Josey,Toni K. Choueiri +11 more
TL;DR: PT2385 has a favorable safety profile and is active in patients with heavily pretreated ccRCC, validating direct HIF-2α antagonism for the treatment of patients withccRCC.
Journal ArticleDOI
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Toni K. Choueiri,Todd M. Bauer,Kyriakos P. Papadopoulos,Elizabeth R. Plimack,Jaime R. Merchan,David F. McDermott,M. Dror Michaelson,Leonard Joseph Appleman,Sanjay Thamake,Rodolfo F. Perini,Naseem J. Zojwalla,Eric Jonasch +11 more
TL;DR: Belzutifan (MK-6482) as mentioned in this paper is a small molecule inhibitor of HIF-2α, which is a transcription factor that frequently accumulates in clear cell renal cell carcinoma (ccRCC), resulting in constitutive activation of genes involved in carcinogenesis.
Journal ArticleDOI
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
A. Keith Stewart,Meletios A. Dimopoulos,Tamas Masszi,Ivan Spicka,Albert Oriol,Roman Hájek,Laura Rosiñol,David S. Siegel,Ruben Niesvizky,Andrzej Jakubowiak,Jesús F. San-Miguel,Heinz Ludwig,Jacqui Buchanan,Kim Cocks,Xinqun Yang,Biao Xing,Naseem J. Zojwalla,Margaret Tonda,Philippe Moreau,Antonio Palumbo +19 more
TL;DR: KRd improves GHS/QoL without negatively affecting patient-reported symptoms when compared with Rd, and data further support the benefit of KRd in patients with relapsed multiple myeloma.
Journal ArticleDOI
Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).
Toni K. Choueiri,Elizabeth R. Plimack,Todd M. Bauer,Jaime R. Merchan,Kyriakos P. Papadopoulos,David F. McDermott,M. Dror Michaelson,Leonard Joseph Appleman,Sanjay Thamake,Naseem J. Zojwalla,Eric Jonasch +10 more
TL;DR: MK-6482 is a first-in-class small molecule HIF-2α inhibitor that blocks the heterodomain of HIF)-2α that is a key oncogenic driver in RCC.